ArticleOncology letters2015
MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- MicroRNAs as Potential Biomarkers of Post-Traumatic Epileptogenesis: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- An overview of challenges associated with exosomal miRNA isolation toward liquid biopsy-based ovarian cancer detection.Heliyon · 2024Review
- DICER-AS1 functions as competing endogenous RNA that targets CSR1 by sponging microRNA-650 and suppresses gastric cancer progression.The Journal of international medical research · 2021Article
- MicroRNA-664a-3p inhibits the proliferation of ovarian granulosa cells in polycystic ovary syndrome and promotes apoptosis by targeting BCL2A1.Annals of translational medicine · 2021Article
- Identification and Confirmation of the miR-30 Family as a Potential Central Player in Tobacco-Related Head and Neck Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
- An alternative miRISC targets a cancer-associated coding sequence mutation in FOXL2.The EMBO journal · 2020Article
- Genetic Variations in miR-30 Family Member Regulatory Regions Are Associated with Breast Cancer Risk in a Chinese Population.BioMed research international · 2020Article
- MiR-140-5p inhibits cell proliferation and metastasis by regulating MUC1 via BCL2A1/MAPK pathway in triple negative breast cancer.Cell cycle (Georgetown, Tex.) · 2019Article
- miR-30 Family Reduction Maintains Self-Renewal and Promotes Tumorigenesis in NSCLC-Initiating Cells by Targeting Oncogene TM4SF1.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- FOXL2C134W-Induced CYP19 Expression via Cooperation With SMAD3 in HGrC1 Cells.Endocrinology · 2018Article
- MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer.Journal of oncology · 2018Review
- miR-30 Family: A Promising Regulator in Development and Disease.BioMed research international · 2018Review
- Changes of Microrna Levels in Plasma of Patients with Rectal Cancer during Chemoradiotherapy.International journal of molecular sciences · 2017Article
- miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples.OncoTargets and therapy · 2017Article
- New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.International journal of molecular sciences · 2016Review
- Circulating microRNAs in follicular fluid, powerful tools to explore in vitro fertilization process.Scientific reports · 2016Article
- Overexpression of miR-30a in lung adenocarcinoma A549 cell line inhibits migration and invasion via targeting EYA2.Acta biochimica et biophysica Sinica · 2016Article
- MiR-30a regulates the proliferation, migration, and invasion of human osteosarcoma by targeting Runx2.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients.Journal of experimental & clinical cancer research : CR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FOXL2 is a transcription factor that is essential for ovarian development. Somatic mutations of FOXL2 are associated with ovarian granulosa cell tumorigenesis. In the present study, the expression of FOXL2 was suppressed by microRNAs using the Ago2 knockdown method in COV434 cells. Online bioinformatics tools were utilized to predict that FOXL2 expression may be repressed by miR-30 family members, and dual luciferase assay and western blotting were performed to demonstrate that FOXL2 is a target gene of miR-30a, which is relatively abundant in COV434 cells. Furthermore, miR-30a overexpression upregulates BCL2A1, IER3 and cyclin D2 expression by inhibiting FOXL2. miR-30a is known to function as a tumor suppressor in breast cancer, small cell lung cancer and colorectal carcinoma; however, the present study revealed an opposing function of miR-30a as an oncogene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.